NPS Pharmaceuticals Inc., of Bedminster, N.J., reported findings from the Phase III REPLACE study of Natpara (recombinant human parathyroid hormone), showing that Natpara initiated bone remodeling as demonstrated by significant increases in bone turnover markers.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST